Ascendis Pharma A/S expected to post a loss of €2.23 a share - Earnings Preview

Ascendis Pharma A/S

23/08/2021 12:14

* Ascendis Pharma A/S  ASND.OQ   ASND.O  is expected to show a
fall in quarterly revenue when it reports results on August 25. 
* The Hellerup, Denmark-based company is expected to report   a
41.1% decrease in revenue to €845.5 thousand from €1.44 million
a year ago, according to the mean estimate from 8 analysts,
based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Ascendis Pharma A/S is
for a loss of €2.23 per share. For the same quarter last year,
the company reported a loss of €1.97 per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 12 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Ascendis Pharma
A/S is $190​, about 36.6% above​ its last closing price
of $120.45. ​​​
* Previous quarterly performance (using preferred earnings
measure in euros). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -1.70       -1.71      -1.17     Beat    31.4
 Dec. 31 2020  -1.59       -1.55      -2.64     Missed  -70.3
 Sep. 30 2020  -1.58       -1.57      -2.31     Missed  -46.7​
 Jun. 30 2020  -1.46       -1.45      -1.97     Missed  -35.6
 Mar.          -1.36​      -1.35      -1.32     Beat    2.1​
 31​ 2020​                                              
 Dec. 31 2019  -1.67       -1.46      -1.70     Missed  -16.5​
 Sep. 30 2019  -1.20       -1.19      -0.53     Beat    55.4
 Jun. 30 2019  -1.22       -1.21      -1.38     Missed  -3.4
 This summary was machine generated August 23 at 11:14 GMT.  All
figures in euros unless otherwise stated